摘要
基础理论:2009年出现的一种新的基因重组H1N1病毒导致了21世纪的第一次流感大流行。目前可用于流感治疗的方法已有耐药性。因此,有必要开发新一代的免疫治疗抗病毒策略。本研究描述了一种新型双功能免疫刺激的siRNA,通过靶向核衣壳蛋白(NP)基因对H1N1猪流感病毒的治疗功效。方法和结果:小干扰RNA(siRNA)针对NP保守区域筛选人肺上皮细胞(A549)抗病毒疗效。此外,通过用NP特异性siRNA结合免疫刺激序列(5’-UGUGU-3’),合成了一种双功能siRNA。此免疫刺激的siRNA(NP-1-is)通过mRNA拷贝数减少(99.58%)说明了强烈的抗病毒作用,病毒相关细胞凋亡及Western blot中核衣壳蛋白抑制的减少。发现此免疫刺激的siRNA比非标记的siRNA更有效。包括剂量依赖性和时间过程的进一步动力学研究表明,NP-1-is siRNA在20-80 nM范围内是更有效的,有显著保护作用并达到48 hpi的。另外,通过实时荧光定量PCR和Western blot分析证实siRNA高免疫抗病毒反应是由于对TLR-7 MyD88、IRF-7和IFN-α表达上调引起的。结论:本研究奠定了使用广谱免疫刺激提高RNAi抗病毒疗法的基础。因此,在对抗流行株的突然出现时本方法是有用的。
关键词: 抗病毒活性,双功能siRNA,小干扰RNA(siRNA),猪流感(H1N1)病毒。
Current Gene Therapy
Title:Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection
Volume: 15 Issue: 5
Author(s): Gaurav Joshi, Paban Kumar Dash, Ankita Agarwal, Shashi Sharma and Manmohan Parida
Affiliation:
关键词: 抗病毒活性,双功能siRNA,小干扰RNA(siRNA),猪流感(H1N1)病毒。
摘要: Rationale: The first influenza pandemic of 21st century was attributed to a novel quadruple reassortant H1N1 virus that emerged in 2009. Currently available therapies for influenza have drugresistant. Therefore, there is a need to develop new generation immunotherapeutic antiviral strategy. This study described the efficacy of a novel bifunctional immunostimulatory siRNAs against H1N1pdm swine flu virus by targeting the Nucleocapsid (NP) gene. Methods & Findings: Small interfering RNAs (siRNA) targeting conserved region of NP were screened for antiviral efficacy in human lung epithelial cells (A549). Further, a bifunctional siRNA was synthesized by combining immunostimulatory sequence (5’-UGUGU-3’) with NP specific siRNA. This immunostimulatory siRNA (NP-1-is) revealed strong antiviral effect through reduction in mRNA copies (99.58%), reduction in virus associated cell apoptosis and inhibition of nucleocapsid protein in western blot. This immunostimulatory siRNA was found more effective than nontagged siRNA. Further studies including dose dependent and time course kinetics revealed that the NP-1-is siRNA is more effective at 20-80 nM with significant protection upto 48 hpi. Besides, the qRT-PCR and western blot analysis confirmed higher antiviral response of immunostimulatory siRNA was due to upregulation of TLR-7 MyD88, IRF-7 and IFN-α. Conclusions: This study paves the way for broad-spectrum RNAi-based therapeutics using immunostimulatory motif towards improved antiviral effect. Hence this approach will be useful to confront the sudden emergence of pandemic strains.
Export Options
About this article
Cite this article as:
Joshi Gaurav, Kumar Dash Paban, Agarwal Ankita, Sharma Shashi and Parida Manmohan, Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812120547
DOI https://dx.doi.org/10.2174/1566523215666150812120547 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functionalized Silver Nanoparticles for Sensing, Molecular Imaging and Therapeutic Applications
Current Nanomedicine MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses
Current Cancer Drug Targets Genetics of Preneoplasia: Lessons from Lung Cancer
Current Molecular Medicine NF-κB-Induced Upregulation of miR-548as-3p Increases Invasion of NSCLC by Targeting PTEN
Anti-Cancer Agents in Medicinal Chemistry Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery Magnetic Nanoparticles for Cancer Therapy
Current Nanoscience Immobilization Techniques Applied to the Development of Biocatalysts for the Synthesis of Nucleoside Analogue Derivatives
Current Pharmaceutical Design Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Current Organic Synthesis Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems
Pharmaceutical Nanotechnology Novel Synthesis, Reactions and anti-Cancer Activities of 4,4-Benzene-1,4- diylbis(6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile)
Current Organic Chemistry Targeting Tumorangiogenesis in Lung Cancer by Suppression of VEGF and its Receptor - Results from Clinical Trials and Novel Experimental Approaches
Current Medicinal Chemistry